YTTRIUM Y 90 CLIVATUZUMAB TETRAXETAN
drugOn this page
Also known as 90HY-PAM490Y-HPAM490Y-HPAMA4HPAM-DOTA HY-PAM4IMMU-107Pan-cideS9S0HY-PAM4Ytrio (90y) clivatuzumab tetraxetanYttrium (90y) clivatuzumab tetraxetan
Summary
Yttrium Y 90 Clivatuzumab Tetraxetan (CHEMBL2108708) is a phase-3 clinical-stage antibody; indicated across 1 condition including exocrine pancreatic carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 1 condition
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108708 |
| Name | YTTRIUM Y 90 CLIVATUZUMAB TETRAXETAN |
| Type | Antibody |
| Max phase | 3 |
Also known as: 90HY-PAM4, 90Y-HPAM4, 90Y-HPAMA4, HPAM-DOTA HY-PAM4, IMMU-107, Pan-cide, S9S0HY-PAM4, Ytrio (90y) clivatuzumab tetraxetan, Yttrium (90y) clivatuzumab tetraxetan, Yttrium y 90 clivatuzumab tetraxetan, YTTRIUM Y 90 CLIVATUZUMAB TETRAXETAN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| exocrine pancreatic carcinoma | 3 | MONDO:0005192 | EFO:0002618 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1/PHASE2 | 2 |
| PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01956812 | PHASE3 | TERMINATED | Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer |
| NCT00597129 | PHASE1/PHASE2 | COMPLETED | Safety and Efficacy Study of 90Y-hPAM4 at Different Doses |
| NCT00603863 | PHASE1/PHASE2 | COMPLETED | Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer |
| NCT01510561 | PHASE1 | WITHDRAWN | A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies. |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: exocrine pancreatic carcinoma